Study S001567

A Phase 1B, Randomized, Open-label, Active-controlled, Parallel, Multiple-dose Study Comparing the Safety, Pharmacokinetics and Efficacy of Dehydratech Cannabidiol and Glucagon-like Peptide 1 Agonists Alone and in Combination, in Overweight or Obese, pre-and Type 2 Diabetic Participants.

ClinicalTrials.gov record

Registration

Registration: NCT06648031
Acronym: DehydraTECH
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 148
Start: 2024-12-04
Primary completion: 2025-07-31
Lead sponsor: Lexaria Bioscience Corp.
Conditions: Type2diabetes
Interventions: DRUG:Arm 1 - DehydraTECH-CBD alone; DRUG:Arm 2 - DehydraTECH-semaglutide alone; DRUG:Arm 3 - DehydraTECH-CBD in combination with DehydraTECH-semaglutide; DRUG:Arm 4 - Rybelsus medication (semaglutide) alone; DRUG:Arm 5- Tirzepatide
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Number of participants with treatment-emergent adverse events (TEAEs) and Serious adverse events [Baseline to Day 113 post first dose administration]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.